InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,056.57
(
0.26%
)
Post# of 1509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

guti

Send PM Follow Ignore
Followers 11
Posts 292
Boards Moderated 0
Alias Born 03/11/2011

guti

Re: Smilin_B post# 1065

Sunday, 06/03/2018 8:08:27 PM

Sunday, June 03, 2018 8:08:27 PM

Post# of 1509
Teva got granted a revision to their Olanzapine patent in early 2017, which includes the method of utilizing polymers. Maybe Teva might be interested in obtaining Edge’s polymer delivery system. After all, Dr. Barer became Teva’s Chairman also in early 2017 and first thing he did was to hire Rosemary Crane to the board. Both are also BOD for Edge, Dr. Barer is also their chairman. It seems they do have options.
https://patents.google.com/patent/US20170079985A1/en
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up